Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INOZYME PHARMA, INC.

(INZY)
  Report
Delayed Nasdaq  -  12:06 2022-11-30 pm EST
1.380 USD   -6.76%
11/11Wedbush Lowers Inozyme Pharma's Price Target to $15 From $20, Keeps Outperform Rating
MT
11/10INOZYME PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
11/10Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2022 11/25/2022 11/28/2022 11/29/2022 11/30/2022 Date
1.55(c) 1.42(c) 1.46(c) 1.48(c) 1.38 Last
448 688 150 825 50 348 29 113 102 916 Volume
+4.73% -8.39% +2.82% +1.37% -6.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -68,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,81x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -90,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,83x
Yield 2023 -
Capitalization 59,8 M 59,8 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 50
Free-Float 98,6%
More Financials
Company
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C... 
Sector
Biotechnology & Medical Research
Calendar
11/29 | 12:30pmPresentation
More about the company
Ratings of Inozyme Pharma, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about INOZYME PHARMA, INC.
11/11Wedbush Lowers Inozyme Pharma's Price Target to $15 From $20, Keeps Outperform Rating
MT
11/10INOZYME PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
11/10Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End..
CI
11/10Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updat..
AQ
11/07Inozyme Pharma : IVBM 2022 Poster VSMC proliferation 003 final 1
PU
11/07Inozyme Pharma to Participate in Upcoming Investor Conferences
AQ
11/03Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficien..
AQ
11/03Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 De..
CI
10/31Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
AQ
10/31Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
CI
09/12Inozyme Pharma : ENPP1-Fc expressing AAV vector prevents ectopic tissue calcification and ..
PU
09/06Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
AQ
08/17Inozyme Pharma : INZY Corporate Presentation August 2022
PU
08/15INOZYME PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
08/15Inozyme Pharma : Reports Second Quarter 2022 Financial Results and Provides Business Updat..
PU
More news
News in other languages on INOZYME PHARMA, INC.
11/10Inozyme Pharma, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois..
11/03Inozyme Pharma, Inc. annonce la première auto-administration de l'Inz-701 dans l'essai ..
10/31Inozyme Pharma annonce la publication d'une base de données complète sur les variantes ..
08/15Inozyme Pharma, Inc. annonce ses résultats pour le deuxième trimestre et le semestre cl..
07/26Inozyme Pharma signe un accord de prêt d'un montant maximal de 70 millions de dollars a..
More news
Analyst Recommendations on INOZYME PHARMA, INC.
More recommendations
ETFs positioned on INOZYME PHARMA, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.02%-1.49%United_States
More ETFs positioned on INOZYME PHARMA, INC.
Chart INOZYME PHARMA, INC.
Duration : Period :
Inozyme Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOZYME PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,48 $
Average target price 18,92 $
Spread / Average Target 1 178%
EPS Revisions
Managers and Directors
Axel Bolte President, Chief Executive Officer & Director
Sanjay S. Subramanian Chief Financial Officer
Douglas A. Treco Chairman
Yves Sabbagh Chief Scientific Officer & Senior Vice President
Soojin Kim Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
INOZYME PHARMA, INC.-78.30%60
MODERNA, INC.-31.83%66 521
IQVIA HOLDINGS INC.-24.68%39 470
LONZA GROUP AG-36.15%37 899
ALNYLAM PHARMACEUTICALS, INC.20.76%25 195
SEAGEN INC.-24.08%21 791